CliffBio
small molecule

THEOPHYLLINE

THEOPHYLLINE

Loss of exclusivity—loss of exclusivity
CompanyHospira →See this company's full patent-cliff portfolio

Drug detail

Brand nameTHEOPHYLLINE
Active ingredientTHEOPHYLLINE
Strength100MG
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 1995
Marketing statusDISCN

More from Hospira

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

THEOPHYLLINE patent cliff — loss of exclusivity — | CliffBio